143 related articles for article (PubMed ID: 34296976)
1. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants.
Vahedian-Azimi A; Shojaie S; Banach M; Heidari F; Cicero AFG; Khoshfetrat M; Jamialahmadi T; Sahebkar A
Ann Med; 2021 Dec; 53(1):1227-1242. PubMed ID: 34296976
[TBL] [Abstract][Full Text] [Related]
2. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
[TBL] [Abstract][Full Text] [Related]
3. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
4. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.
Kamal S; Khan MA; Seth A; Cholankeril G; Gupta D; Singh U; Kamal F; Howden CW; Stave C; Nair S; Satapathy SK; Ahmed A
Am J Gastroenterol; 2017 Oct; 112(10):1495-1505. PubMed ID: 28585556
[TBL] [Abstract][Full Text] [Related]
5. Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease.
Sharma R; Simon TG; Hagström H; Lochhead P; Roelstraete B; Söderling J; Verna EC; Emond J; Ludvigsson JF
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):749-759.e19. PubMed ID: 37121528
[TBL] [Abstract][Full Text] [Related]
6. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.
Simon TG; King LY; Zheng H; Chung RT
J Hepatol; 2015 Jan; 62(1):18-23. PubMed ID: 25135867
[TBL] [Abstract][Full Text] [Related]
7. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
Mohanty A; Tate JP; Garcia-Tsao G
Gastroenterology; 2016 Feb; 150(2):430-40.e1. PubMed ID: 26484707
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
[TBL] [Abstract][Full Text] [Related]
9. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.
Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT
Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695
[TBL] [Abstract][Full Text] [Related]
10. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
Zheng YX; Zhou PC; Zhou RR; Fan XG
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):759-766. PubMed ID: 28240613
[TBL] [Abstract][Full Text] [Related]
11. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis.
Wong JC; Chan HL; Tse YK; Yip TC; Wong VW; Wong GL
Aliment Pharmacol Ther; 2017 Nov; 46(10):1001-1010. PubMed ID: 28940673
[TBL] [Abstract][Full Text] [Related]
12. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
[TBL] [Abstract][Full Text] [Related]
13. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.
Kim RG; Loomba R; Prokop LJ; Singh S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1521-1530.e8. PubMed ID: 28479502
[TBL] [Abstract][Full Text] [Related]
14. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance.
Cheung KS; Mak LY; Lam LK; Fung J; Liu F; Seto WK; Yuen MF
Hepatol Int; 2021 Aug; 15(4):881-891. PubMed ID: 33988834
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.
Gu Y; Yang X; Liang H; Li D
BMC Gastroenterol; 2019 Dec; 19(1):231. PubMed ID: 31888534
[TBL] [Abstract][Full Text] [Related]
16. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis.
Li X; Sheng L; Liu L; Hu Y; Chen Y; Lou L
BMC Gastroenterol; 2020 Apr; 20(1):98. PubMed ID: 32272891
[TBL] [Abstract][Full Text] [Related]
17. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Goh MJ; Sinn DH; Kim S; Woo SY; Cho H; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Hepatology; 2020 Jun; 71(6):2023-2032. PubMed ID: 31556128
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis.
Wong YJ; Qiu TY; Ng GK; Zheng Q; Teo EK
J Clin Gastroenterol; 2021 Aug; 55(7):615-623. PubMed ID: 33606427
[TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
20. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
